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Identification of Pathway-Specific SerumBiomarkers of
Response to Glucocorticoid and Infliximab Treatment
in Children with Inflammatory Bowel Disease
Christopher R. Heier, PhD1, Alyson A. Fiorillo, PhD1, Ellen Chaisson, MSN, RN, CPNP-AC2, Heather Gordish-Dressman, PhD1,3,
Yetrib Hathout, PhD1,3, Jesse M. Damsker, PhD1,4, Eric P. Hoffman, PhD1,3,4 and Laurie S. Conklin, MD1,2
OBJECTIVE: Serum biomarkers may serve to predict early response to therapy, identify relapse, and facilitate drug development in
inflammatory bowel disease (IBD). Biomarkers are particularly important in children, in whom achieving early remission and
minimizing procedures are especially beneficial.
METHODS: We profiled protein and micro RNA (miRNA) in serum from patients pre- and post-therapy, to identify molecular
markers of pharmacodynamic effect. Serum was obtained from children with IBD before and after treatment with either
corticosteroids (prednisone; n= 12) or anti-tumor necrosis factor-α biologic (infliximab; n= 7). Over 1,100 serum proteins were
assayed using aptamer-based SOMAscan proteomics, and 22 miRNAs analyzed by quantitative real time PCR. Concordance of
longitudinal changes between the groups was used to identify markers responsive to treatment. Bioinformatic analysis was used
to build insight into mechanisms of changes in response to treatment.
RESULTS: We identified 18 proteins and three miRNAs responsive to both prednisone and infliximab. Eight markers that
decreased are associated with inflammation and have gene promoters regulated by nuclear factor (NF)-κB. Several that increased
are associated with resolving inflammation and tissue damage. We also identified six markers that appear to be steroid-specific,
three of which have glucocorticoid receptor binding elements in their promoter region.
CONCLUSIONS: Serum markers regulated by the inflammatory transcription factor NF-κB are potential candidates for
pharmacodynamic biomarkers that, if correlated with later outcomes like endoscopic or histologic healing, could be used to
monitor treatment, optimize dosing, and enhance drug development. The pharmacodynamic biomarkers identified here hold
potential to improve both clinical care and drug development. Further studies are warranted to investigate these markers as early
predictors of response, or possibly surrogate outcomes.
Clinical and Translational Gastroenterology (2016) 7, e192; doi:10.1038/ctg.2016.49; published online 15 September 2016
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INTRODUCTION
The onset, symptoms, and progression of inflammatory bowel
disease (IBD) are highly variable and unpredictable. A variety
of phenotypes exist; extra-intestinal inflammation may man-
ifest as uveitis, arthritis, or growth failure in children. Therapies
for IBD are focused on the induction and maintenance of
remission, and the prevention of longer-term complications of
chronic inflammation, such as relapsing disease, steroid-
dependence, malnutrition, growth-stunting in children, and
colorectal cancer. There is a disconnect between patient
symptoms and mucosal inflammation, and increasing evi-
dence in adults with IBD shows that long-term clinical
outcomes are not improved by treating to symptom remission,
but are improved by directly targeting mucosal
inflammation.1,2 Practically, using ileocolonoscopy and ima-
ging to monitor disease response requires waiting 3–6 months
for cycles of repair to occur, followed by re-assessment of
healing by endoscopy or imaging, adjusting therapy based on
these results, and then repeating the evaluation again.3
Though this may currently be the optimal approach available,
acceptance of repeated colonoscopy as a widespread clinical
practice or as a clinical trial endpoint may be limited by patient
discomfort, procedural risk, anesthesia, and high cost. This is
a particularly important issue in pediatric clinical care, and a
barrier to recruitment in pediatric clinical trials.4
There is a need for biomarkers to predict response to
therapy and optimize treatment regimens to improve quality of
life. Such biomarkers are particularly important in children.5
Facing a long or lifetime duration of disease encompassing
important stages of development, the disease manifestations,
side-effects of current therapies, and exposure to repeated
invasive procedures may have greater negative impacts on
children and their families. In addition to treatment decisions,
serum biomarkers may inform earlier dosing, safety, and
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efficacy decisions in pediatric clinical trials. Currently, a small
number of clinically-utilized biomarkers of disease response
are available to the IBD clinician, as recently reviewed in
Sands et al.6
New candidates have been identified as potential blood-
based biomarkers in IBD, but the effect of specific treatments on
the prospective change of these biomarkers has not been
investigated. These include proteins, as well as micro RNAs
(miRNAs), which are emerging as promising treatment-
responsive biomarkers. Recently, serum SERPINA1 (α-1-
antitrypsin) was shown to differentiate between mild and more
severe forms of adult ulcerative colitis (UC), and appears to be
superior to C-reactive protein in this regard.7,8 In two recent
studies, circulating miRNAs were measured in patients with
Crohn's disease (CD) and/or UC. One study found 24 serum
miRNAs differentially expressed in children with CD.9 The other
study found three sets of peripheral blood miRNAs that
distinguish between active CD, UC, and healthy adult
patients.10 Bridging specific biomarkers to drug response (for
example, pharmacodynamic biomarkers) will be a necessary
step in establishing a biomarker as a treatment monitoring tool
or as an outcome measure in clinical trials. In this exploratory
study, our goal was to carry out a broad discovery of
pharmacodynamic biomarkers that show response to corticos-
teroid and anti-tumor necrosis factor-α (TNFα) biologic treat-
ment of pediatric IBD. Our hypothesis was that serum
inflammatory proteins and miRNAs that lie in the pathway of
drug effect, and that change in the same direction after
treatment with both classes of drugs, are candidates for further
study as potential surrogate outcome measures.
METHODS
Ethics statement. All work was conducted according to
relevant national and international guidelines, reviewed and
approved by the Institutional Review Board of Children’s
National Health System.
Patients, treatment, and serum collection. Patients ran-
ged in age from 9 to 19 years, and were all cared for at
Children’s National Health System, a quaternary-care, free-
standing children’s hospital in Washington, DC, USA that
serves ~400 IBD patients. Patients with IBD were randomly
recruited for this study, which was designed for the collection
of serum samples pre- and post-treatment to evaluate
longitudinal changes in proteins and miRNAs. Demographics
and clinical characteristics of the two patient groups are
provided in Table 1. All were outpatients, treated as indicated
per their gastroenterologist; follow-up serum samples were
drawn at the time of a clinically indicated lab-draw. There
were no entry disease scores or criteria. Most patients were
evaluated by ileocolonoscopy or magnetic resonance enter-
ography prior to starting therapy. Two patients were started
on infliximab to treat perianal disease. One child was started
on infliximab for growth failure. Two patients reported no
symptoms, but therapy was escalated to infliximab because
of elevated serum inflammatory markers and endoscopic
inflammation. For this study, we selected patients treated with
infliximab who were not recently exposed to corticosteroids or
immunomodulators.
Corticosteroid-treated patients received daily oral predni-
sone at standard 1 mg/kg dosing up to a maximum of 40 mg
daily. All but one steroid-treated patient was newly diagnosed,
without baseline exposure to other medications. The one
previously diagnosed patient with CD had only been exposed
to mesalamine at diagnosis. None of the infliximab-treated
patients were treated with concurrent steroids or immunomo-
dulators, and received standard induction dosing of infliximab
(5 mg/kg/dose) at time 0 and week 2.
As our goal was to identify pharmacodynamic effects of
therapy, we chose a longitudinal approach.We focused, in this
initial discovery study, on obtaining an early read-out of
physiologic biomarker change after administration of therapy.
We chose not to wait for a longer period to fully assess clinical
or endoscopic response or remission (typically 12–52 weeks
of treatment), as this would have the potential to introduce
more variability and dilute a pharmacological effect. Two blood
samples were obtained from each patient, one before
Table 1 Patient clinical characteristics, treatment dosing and schedule, clinical
scores, and serum inflammatory markers
Study description Prednisone
cohort
Infliximab
cohort
Number of patients 12 7
Age (years) 12.2±2.4 15.7± 1.8
Males:females 6 M:6 F 4 M:3 F
Patient diagnoses 10 CD:2 UC 7 CD
Disease years 11 newly dx’d
1 CD 4.1 yrs* 2.1±1.6
Paris classification disease location53
L1 (distal 1/3 ileum) 1
L1,L4b (distal 1/3 ileum, upper GI distal to
ligament of Treitz
1
L2 (colonic) 2 1
L2, p (colonic, perianal disease) 1
L3 (ileocolonic) 4 1
L3,p (ileocolonic, perianal disease) 1 4
L3,L4a (ileocolonic, upper GI proximal to
the ligmant of Treitz
1
Treatment time (weeks) 9.4± 4.4 6.1±0.3
Treatment regimen Daily
prednisone
Two infu-
sions, 5 mg/
kg
Dose range 0.6–1 mg/kg 2 weeks apart
CRP levels (mg/dl, normal 0.06–0.79)
Pre-treatment 3.7± 3.1 1.1±1.0
Post-treatment 0.5± 0.8 0.6±0.5
P-value 0.003 0.2
ESR (mm/h, normal 0–20)
Pre-treatment 44.4± 32.0 31.0±19.7
Post-treatment 22.5± 14.9 12.3± 6.5
P-value 0.06 0.07
PCDAI
Pre-treatment 36.5± 16.4 16.4±11.4
Post-treatment 11.0±7.8 9.6±12.1
P-value 0.06 0.07
PUCAI (2 UC patients treated with
prednisone)
Pre-treatment 70, 85**
Post-treatment 15, 40**
CD, Crohn’s disease; CRP, C-reactive protein; ESR, erythrocyte sedimentation
rate; GI, gastrointestinal; PCDAI, Patient Crohn’s Disease Activity Index; UC,
ulcerative colitis.
(*patient received 5-ASA prior to study; values are mean± s.d.; paired t-test).
(**two patient scores).
Anti-Inflammatory Biomarker Discovery
Heier et al.
2
Clinical and Translational Gastroenterology
treatment (baseline control), and one after treatment with
either prednisone or infliximab (paired sample for longitudinal
analysis). Duration of steroid treatment ranged from 3 to
18 weeks. For infliximab, post-drug samples were drawn at
6 weeks after treatment initiation, just prior to the third
induction dose. Pediatric Crohn’s Disease Activity Index and
Pediatric Ulcerative Colitis Activity Index were recorded at
both pre- and post-treatment time points, as were C-reactive
protein and erythrocyte sedimentation rate.
Proteomic profiling. Proteins were profiled using a SOMAs-
can assay (SomaLogic; Boulder, CO, USA) that analyzed
either 1,120 unique proteins (prednisone group; 1st-
generation panel), or 1,300 proteins (infliximab group; 2nd-
generation panel), as previously described.11,12 In total, 70 μl
of serum per patient was used to measure all proteins in a
multiplex manner. Each aptamer targets a specific protein
and is tagged with a unique DNA sequence permitting its
quantification. Protein-aptamer levels were quantified on
Agilent hybridization arrays in relative fluorescent units and
analyzed using SomaSuite version 1.0 (SomaLogic). Protein
levels were log transformed and tested to verify normality.
Eleven patients were included in the prednisone group (nine
CD, two UC) and seven patients in the infliximab group
(seven Crohn’s). The two treatment groups were analyzed
separately using paired t-tests, comparing baseline to post-
treatment values. A P-value of 0.05 was set as the
significance threshold, without adjustment for multiple com-
parisons. To reduce false-positive discovery in this setting, we
used an evidence-based approach where results from the
two groups were cross-referenced. Proteins that significantly
changed in the same direction in each of the two separate
groups were considered candidate biomarkers.
miRNA profiling. RNA was isolated using TRIzol with
overnight isopropanol precipitation. The same patient sam-
ples were analyzed for miRNA, with the addition of one more
CD patient in the prednisone group. A total of 12 patients
were included in the prednisone group (10 CD and 2 UC) and
7 in the infliximab group (7 CD). We used separate aliquots of
the same patient serum samples used for SOMAscan, plus
one additional prednisone-treated patient. We performed
targeted quantification of 24 miRNAs selected for their prior
detection in either inflammation or steroid-responses (primer/
probe sets in Supplementary Table S1).13 Complementary
DNA was synthesized using multiplexed RT primers, pre-
amplified using TaqMan PreAmp Master Mix (Life Technolo-
gies, Carlsbad, CA), and miRNAs quantified using individual
TaqMan assays on an ABI 7900HT.14 miRNAs were normal-
ized to the geometric mean of multiple control genes,
followed by statistical comparison of baseline to post-
treatment values by paired t-test.15,16 Control miRNAs (hsa-
miR-342-3p and hsa-miR-150-5p) were previously identified
as stable control reference miRNAs in IBD patient serum.9
Bioinformatics. We examined regulation of gene promoters
for each biomarker candidate to gain insight into mechanisms
of their response to treatment. Promoter binding by the
inflammatory transcription factor nuclear factor (NF)-κB or the
glucocorticoid receptor (GR) steroidal transcription factor was
examined using chromatin immunoprecipitation sequencing
(ChIP-seq) data from ENCODE. ChIP-seq data from ENCODE
and Factorbook was used to query physical binding of
candidate gene promoters.17,18 Data/images were produced
using UCSC Genome Browser Release 4 with alignment to
human reference genome GRCh37/hg19.17,19 Within ChIP-
seq peaks, sequences were downloaded and analyzed using
UCSC and/or JASPAR version 5.0a.20 ChIP-seq data sets
were obtained from TNFα-induced human immune cells
(RelA), and dexamethasone-induced human lung, liver and
endometrial cell lines (NR3C1). Heat maps were generated
with Hierarchical Clustering Explorer Version 3.5 (Human
Computer Interaction Laboratory; University of Maryland,
College Park, MD, USA). To examine interactions between
the identified molecular markers, we performed gene pathway
analysis using Ingenuity Pathway Analysis, IPA Version
26127183 (QIAGEN, Hilden, Germany).
RESULTS
Proteomic responses to treatment. Aptamer-based pro-
teomics was used to profile serum protein levels pre- and
post-treatment (Figure 1). For prednisone-treated children,
213 proteins showed significant changes (Supplementary
Table S2). For infliximab-treated children, 94 proteins showed
significantly different levels after treatment (Supplementary
Table S3). Eighteen proteins showed a significant change in
Figure 1 Summary of serum protein changes. (a) Venn diagram of proteomics
results analyzing serum changes of proteins in the Prednisone and Infliximab
treatment groups. (b) Heat map visualization of the fold changes of the 16 overlapping
protein markers within each patient. (red= increased, green= decreased).
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the same direction for both prednisone and infliximab therapy
(Table 2). Of these, five proteins showed a significant
decrease in response to treatment. These proteins have
known functions associated with inflammation, including α-1-
antitrypsin (SERPINA1), insulin-like growth factor binding
protein 1 and 2 (IGFBP1 and IGFBP2), resistin (RETN), and
C-C motif chemokine 23 (CCL23).
The specific SOMAscan panels utilized for the two groups
were slightly different, in that the prednisone-treated group
was tested using a 1,120 protein panel, whereas the
infliximab-treated group was tested with a newer 1,300 protein
panel. Thus, ~ 180 additional proteins were assayed in the
infliximab group. Eleven of these significantly changed with
infliximab, but were not able to be cross-referenced in the
prednisone-treated data set (Supplementary Table S4). These
include CD177 antigen (CD177), chitinase-3-like protein 1
(CHI3L1), protein S100A12 (S100A12), and C-X-C motif
chemokine 9 (CXCL9), which are inflammatory proteins that
decreased with infliximab.
To identify potential steroid-specific responses, we used
bioinformatics to screen differentially expressed proteins for
established interactions with either the GR or TNFα. We found
that the genes encoding three of these proteins were direct
targets of the GR (Figure 2). These include apolipoprotein E,
complement subcomponent C1r, and reticulon 4. An additional
two, apolipoprotein B and afamin, were direct targets of
apolipoprotein E. Other markers were more indirectly con-
nected to the GR or were regulated by TNFα as well. Because
they changed exclusively in response to prednisone, and are
known to be regulated by the GR, these five proteins may
represent steroid-specific biomarkers.
We did not aim to correlate biomarkers with established
clinical or biochemical response following this rather short-
treatment period. However, we did note that a majority of
patients in both groups did show expected improvement in
clinical and biochemical measures following treatment. Pre-
dnisone treatment (n= 12) resulted in a significant
improvement in C-related protein (Po0.005) and pediatric
Crohn’s disease index (Po0.001, n= 10 Crohn’s patients),
along with a trend of improvement in erythrocyte sedimenta-
tion rate (P=0.06). Infliximab treatment (n=7) led to a trend of
improvement in each of these three measures (C-related
Table 2 Differential expression of serum proteins by both treatment groups (prednisone and infliximab), indicating the direction of change, and a description of the
general protein function
Glucocorticoid cohort Infliximab cohort
Gene ↑ or ↓ P-value Pre (RFU)a Post (RFU)a P-value Pre (RFU)a Post (RFU)a Description
SERPINA1 ↓ o0.001 6.90± 0.26 6.52± 0.17 0.017 6.77± 0.15 6.65± 0.07 Increased in inflammation
IGFBP2 ↓ 0.003 10.88± 0.47 10.17± 0.34 0.006 6.90± 0.40 6.40± 0.48 Increased in inflammation
IGFBP1 ↓ 0.006 8.34± 0.65 7.01± 0.82 0.025 7.92± 0.86 6.92± 0.87 Increased in inflammation
RETN ↓ 0.025 8.49± 0.53 8.13± 0.43 0.004 8.31± 0.45 8.06± 0.36 Increases cytokines
CCL23 ↓ 0.030 8.23± 0.31 7.97± 0.21 0.020 7.93± 0.37 7.66± 0.37 Chemotactic for monocytes
P4HB ↑ o0.001 6.02± 0.05 6.14± 0.07 0.001 6.10± 0.09 6.22± 0.09 Integrin binding
CNDP1 ↑ o0.001 9.02± 0.35 9.61± 0.40 0.005 8.26± 0.44 8.55± 0.50 Improved cancer prognosis
CDH3 ↑ o0.001 9.76± 0.20 10.01± 0.17 0.044 10.34± 0.16 10.47± 0.15 Cell adhesion
CCL25 ↑ 0.006 7.53± 0.51 7.92± 0.68 0.005 7.86± 0.55 8.21± 0.57 Protective in colitis
SPOCK2 ↑ 0.011 6.48± 0.29 6.81± 0.16 0.018 6.71± 0.24 6.84± 0.19 ECM binding
ADGRE2 ↑ 0.021 5.90± 0.25 6.15± 0.32 0.036 6.62± 0.23 6.79± 0.16 Promotes cytokine release
CHRDL1 ↑ 0.021 7.69± 0.14 7.81± 0.12 0.010 7.84± 0.16 7.98± 0.14 BMP4 antagonist
IFNA2 ↑ 0.024 5.27± 0.12 5.33± 0.09 0.023 4.98± 0.09 5.04± 0.10 JAK/STAT signaling
NCAM1 ↑ 0.026 8.89± 0.31 9.11± 0.21 0.030 9.10± 0.23 9.26± 0.20 Cell adhesion
AGT ↑ 0.033 8.67± 0.21 8.84± 0.20 0.022 8.86± 0.14 8.98± 0.20 Vasoconstriction
IgM ↑ 0.034 7.45± 0.39 7.64± 0.50 0.036 7.94± 0.28 8.10± 0.16 B-cell antibody
CNTF ↑ 0.042 6.47± 0.13 6.53± 0.12 0.004 5.73± 0.08 5.79± 0.11 Protective in inflammation
CD36 ↑ 0.046 8.05± 0.33 8.33± 0.44 0.039 8.76± 0.32 8.96± 0.28 Pro-resolution M2
BMP4, bone morphogenetic protein 4; ECM, extracellular matrix; JAK/STAT, Janus kinase and a Signal Transducer and Activator of Transcription; M2, M2
macrophage; RFU, relative fluorescent units.
aValues are log transformed mean± s.d.
Figure 2 Potential steroid-specific protein markers. To identify potential steroid-
specific biomarkers, we used Ingenuity Pathway Analysis to screen proteins
significantly altered by prednisone but not by infliximab. (a) Three proteins were found
to be directly regulated by the glucocorticoid receptor (GR, or NR3C1) but not by TNF.
An additional two were found to be regulated by one of its direct targets, but not by
TNF. These five proteins (marked by a red box) were selected as potential steroid-
specific markers. (b) Proteomic expression data for these five targets demonstrates
that these were affected by prednisone treatment but not by infliximab treatment.
(aValues are log transformed mean± s.d.; red= increased, blue= decreased,
green= drug, yellow= direct drug targets, NR3C1= glucocorticoid receptor).
Anti-Inflammatory Biomarker Discovery
Heier et al.
4
Clinical and Translational Gastroenterology
protein, P=0.2; Pediatric Crohn’s Disease Activity Index,
P= 0.09; erythrocyte sedimentation rate, P=0.07). Non-
statistically significant trends also likely reflect our small
sample size.
miRNA responses to treatment. We identified four miRNAs
that responded to treatment using quantitative real time PCR
(Figure 3). Of these, three decreased with both prednisone and
infliximab: miR-146a, miR-320a, and miR-146b. These miR-
NAs have been associated with inflammation. Notably, in
individual patients, it appeared there may be a relationship
between the size of effect and the duration of prednisone
treatment. In addition, the two UC patients appeared to show a
different pattern of miRNA response to treatment. Interestingly,
other groups have found differences in serum miRNAs
between Crohn’s and UC, which may be consistent with our
observations.10 A fourth miRNA, miRNA-486, showed a
significant change in response to prednisone (Po0.01), but
not to infliximab. These data provide a panel of miRNAs that
are responsive to two anti-inflammatory drugs with different
mechanisms of action.
Bioinformatic analysis of gene regulation pathways. We
found in ChIP-seq data and established literature that the
majority of markers, which decreased with both drugs have
gene promoters directly bound by NF-κB (Figure 4).18,21–26
Figure 3 Serum microRNA levels change with prednisone or infliximab treatment. Levels of miRNAs were assayed by qRT-PCR. Bar graphs of the percent baseline levels for
each treatment group, as well as change in expression for each individual patient, are provided for each miRNA. (a) miR-146a in response to prednisone (a) and infliximab (a’).
miR-320a in response to prednisone (b) and infliximab (b’). miR-146b in response to prednisone (c) and infliximab (c’), note; four post-treatment and two baseline samples had
miR-146b levels below detection threshold. (d) miR-486 in response to prednisone (d) and infliximab (d’). (*Po0.05, **Po0.01; paired t-test).
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This includes the protein SERPINA1, which is known to be
elevated in IBD, and three miRNAs (miR-146a, 146b, and
320a). When we assessed steroid receptor binding, we found
genes for three of the steroid-specific markers possess
promoter elements directly bound by the GR, including
complement subcomponent C1r and miR-486 (Figure 4).
Together, this indicates that gene expression regulation for
these markers is consistent with their response to treatment.
We found that 11 of the identified proteins are established to
have connections to each other through interactions with NF-
κB, TNFα, and/or the GR (Figure 5). This further establishes
these molecular changes as part of a systemic network
response to effective anti-inflammatory treatment.
DISCUSSION
We have identified 18 proteins and 3 miRNAs that are
responsive to both prednisone and infliximab treatment. Both
of these drugs target inflammatory TNFα and NF-κB signaling,
but they do so via distinctly different mechanisms. Infliximab is
an antibody that specifically binds to and inactivates the TNFα
cytokine (ligand), blocking its NF-κB-mediated antiapoptotic
effects.27 In contrast, prednisone is a corticosteroid that binds to
and activates the GR. Activated GR then binds to NF-κB
complexes to inhibit downstream TNFα-mediated inflamma-
tion.28 However, prednisone-activated GR shows many addi-
tional activities outside of NF-κB transrepression, as it also
bindsdirectly to hundreds ofDNAelements that affect additional
gene expression pathways.29 By overlaying molecular changes
in serum from patients treated with these partially overlapping
drug mechanisms, we have identified ~20 serum-based
pharmacodynamic markers of anti-inflammatory therapies.
All five of the NF-κB-regulated proteins that decrease with
treatment have roles in inflammation. The first is α-1-
antitrypsin, or SERPINA1, a serine protease inhibitor that
induces T-regulatory cell expansion.30–32 Notably, serum
SERPINA1 already shows potential as a diagnostic biomarker
in IBD.7,8 A second protein, CCL23, is a chemokine known to
be elevated in both IBD and rheumatoid arthritis.33,34 NF-κB
regulates CCL23, which then increases expression of pro-
inflammatory cytokines, chemokines and adhesion
molecules.35 Another protein marker, resistin, or RETN, is
an adipocytokine that shows species-specific tissue expres-
sion and is induced by TNFα in human macrophages.25,36
Corticosteroids are known to affect RETN, though these
effects may be time-specific.37,38 Finally, both IGFBP1 and
IGFBP2 decrease with prednisone and infliximab. The IGF-
binding proteins regulate endocrine actions of insulin-like
growth factors, and IGFBP1 is primarily produced by the liver
during states of inflammation. IGFBP2 and IGFBP3 have been
shown to decrease after high-dose corticosteroids in Crohn’s
disease andUC.39 Our results suggest these effects on IGFBP
proteins may not be steroid-specific.
Twelve proteins increased with treatment of IBD by both
drugs. Many of these have a role in resolving tissue damage.
CNTF is a polypeptide hormone, which acts as a growth and
survival factor to reduce inflammatory tissue destruction in a
Figure 4 Promoter analysis of serum markers. (a) Schematic of the gene locus for
miR-146a, illustrating the binding site and sequence of a promoter element bound by NF-
κB. (b) Schematic of the gene locus for C1R, illustrating the binding site and sequence of
a promoter element bound by GR. (c) Summary of promoter analysis and literature data
indicating the marker and known elements associated with its regulation. (H3K4me3=
histone modification associated with active gene promoters, Blue highlight= site of
promoter bound by transcription factor, with relevant sequence provided below
consensus motif sequence logo, M2= expressed by pro-resolution M2 macrophages).
Figure 5 Pathway analysis of serum markers that change in response to
treatment. Gene pathways of serum markers that responded to treatment were
analyzed using Ingenuity Pathway Analysis. Established gene network connections
were present between 11 of the 18 drug-responsive protein markers and NF-κB,
NR3C1, or TNF. (red= increased, blue= decreased, green= drug, yellow= direct
drug targets, NR3C1= glucocorticoid receptor).
Anti-Inflammatory Biomarker Discovery
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variety of injury types.40,41 Cadherin 3, or p-cadherin, is
involved with cell adhesion in epithelial tissues and may be
involved in wound repair.42 CCL25 and CD36 are particularly
interesting as potential efficacy markers in IBD. Both are
expressed by M2 macrophages associated with resolving
inflammation. CCL25 is required for protection against chronic
colitis in animal models.43 CD36 is required, together with
lipolysis, for activation of M2 pro-resolution macrophages.44
Together, these markers may reflect the repair of intestinal
tissue damage in IBD.
We identified threemiRNAs that are responsive to both drugs
and are known to be inducedby inflammatory signaling. Notable
among these is miR-146a, which is elevated in several
inflammatory diseases and is induced by NF-κB in immune
and muscle cells.13,45–47 Interestingly, miR-146a (on chromo-
some 5) has both acute anti-inflammatory affects45 and chronic
pro-inflammatory effects,48 and it is proposed that these
contrasting effects may help in the staging of the inflamma-
tion/resolution process.49 The miR-146 family also includes
miR-146b (on chromosome 10), which we find is affected by
both treatments as well. These two miRNAs have shared gene
targets, although timing of their expression may differ. A
treatment response of this miR-146 family is consistent with
studies in muscular dystrophy, where we find both prednisone
and a novel dissociative steroid (VBP15) reduce TNFα-
mediated induction of miR-146b and miR-146a.13,50 Though
less studied, miR-320a is linked to inflammatory disease as
well. In colon biopsies fromadultswith UC, reducedmiR-320a is
associated with reduced inflammation.51 Together, measuring
levels of these miRNAs could help assess inflammatory
disease, as well as therapeutic response.
The pharmacodynamic biomarkers identified here hold
potential for improving clinical care, and for streamlining
development of new treatments. However, there are several
limitations to our study. This is an exploratory, proof-of-concept
study with limited patient numbers, variable sample timing,
and heterogeneous patient populations. Because our statis-
tical approach did not adjust for multiple comparisons, there is
potential for type II error and false discovery. Further studies
are necessary to replicate these findings, and to develop these
markers as surrogate outcome measures. Summary data
have been included in the Supplementary Data section.
Moving forward, a prospective study with more acute and
less-variable blood sampling, hours or days after treatment,
will define which biomarkers show the earliest responses to
treatment, as well as validate biomarker discovery. Acutely
responsive biomarkers should then be bridged to objective
measures of intestinal inflammation and downstream clinical
outcomes, with larger numbers of pediatric IBD patients
followed out over a longer-term outcome period. This subset of
biomarkers could then be used as outcome measures in drug
development for dose finding studies (Phase 2a), and as
surrogate biochemical outcome measures to support efficacy
(Phase 2b or Phase 3 studies). In addition to biologics and
small molecule inhibitors for IBD therapy, novel anti-
inflammatory drugs with improved safety profiles are in
development for IBD and other chronic inflammatory
disorders.50,52 Based on the successes of this pilot and
feasibility study, drug-specific responses to treatment can be
measured using specific serum biomarkers. Unanswered
questions about the most clinically appropriate biomarkers to
track various components of a complex disease like IBD (for
example, the type and degree of the inflammatory process,
and the state and activity of the healing process) remain. The
time-line of the responses, the sensitivity and specificity of
response over time compared to established (invasive) clinical
measures, cost, and other issues must be addressed.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
• Objective evaluation is necessary to adequately assess
disease response in inflammatory bowel disease (IBD).
• Current disease evaluation tools either use symptom-based
indices that poorly reflect underlying inflammatory disease,
or use invasive, costly, and slow methods like colonoscopy.
WHAT IS NEW HERE
• We used novel aptamer-based proteomics methods to
discover serum proteins that respond to each of two different
anti-inflammatory drugs with known efficacy in IBD.
• SerummiRNAs are nowemerging as stable, well-conserved
serum biomarkers, and we found several miRNAs
responsive to anti-inflammatory treatments.
• Bioinformatic analyses showed that eight markers that
decrease are associated with inflammation and have gene
promoters regulated by NF-κB, a key inflammatory
transcription factor.
1. Shah SC, Colombel JF, Sands BE et al. Mucosal healing is associated with improved long-
term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis. Clin
Gastroenterol Hepatol 2016; 14: 1245–1255.
2. Shah SC, Colombel JF, Sands BE et al. Systematic review with meta-analysis: mucosal
healing is associated with improved long-term outcomes in Crohn's disease. Aliment
Pharmacol Ther 2016; 43: 317–333.
3. Peyrin-Biroulet L, Sandborn W, Sands BE et al. Selecting therapeutic targets in inflammatory
bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J
Gastroenterol 2015; 110: 1324–1338.
Anti-Inflammatory Biomarker Discovery
Heier et al.
7
Clinical and Translational Gastroenterology
4. Turner D, Levine A, Walters TD et al. Which PCDAI version best reflects intestinal
inflammation in pediatric Crohn's disease? J Pediatr Gastroenterol Nutr 2016.
5. Hathout Y, Conklin LS, Seol H et al. Serum pharmacodynamic biomarkers for chronic
corticosteroid treatment of children. Sci Rep 2016; 6: 31727.
6. Sands BE. Biomarkers of inflammation in inflammatory bowel disease. Gastroenterology
2015; 149: 1275–1285 e2.
7. Matalon S, Elad H, Brazowski E et al. Serum alpha-1 antitrypsin: a noninvasive marker of
pouchitis. Inflamm Bowel Dis 2015; 21: 589–595.
8. Soendergaard C, Nielsen OH, Seidelin JB et al. Alpha-1 antitrypsin and granulocyte colony-
stimulating factor as serum biomarkers of disease severity in ulcerative colitis. Inflamm
Bowel Dis 2015; 21: 1077–1088.
9. Zahm AM, Thayu M, Hand NJ et al. Circulating microRNA is a biomarker of pediatric Crohn
disease. J Pediatr Gastroenterol Nutr 2011; 53: 26–33.
10. Wu F, Guo NJ, Tian H et al. Peripheral blood microRNAs distinguish active ulcerative colitis
and Crohn's disease. Inflamm Bowel Dis 2011; 17: 241–250.
11. Gold L, Walker JJ, Wilcox SK et al. Advances in human proteomics at high scale with the
SOMAscan proteomics platform. Nat Biotechnol 2012; 29: 543–549.
12. Hathout Y, Brody E, Clemens PR et al. Large-scale serum protein biomarker discovery in
Duchenne muscular dystrophy. Proc Natl Acad Sci USA 2015; 112: 7153–7158.
13. Fiorillo AA, Heier CR, Novak JS et al. TNF-alpha-induced microRNAs control dystrophin
expression in Becker muscular dystrophy. Cell Rep 2015; 12: 1678–1690.
14. Chen C, Ridzon DA, Broomer AJ et al. Real-time quantification of microRNAs by stem-
loop RT-PCR. Nucleic Acids Res 2005; 33: e179.
15. Vandesompele J, De Preter K, Pattyn F et al. Accurate normalization of real-time quantitative
RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;
3: RESEARCH0034.
16. Rieu I, Powers SJ. Real-time quantitative RT-PCR: design, calculations, and statistics. Plant
Cell 2009; 21: 1031–1033.
17. Kent WJ, Sugnet CW, Furey TS et al. The human genome browser at UCSC. Genome Res
2002; 12: 996–1006.
18. Wang J, Zhuang J, Iyer S et al. Sequence features and chromatin structure around the
genomic regions bound by 119 human transcription factors. Genome Res 2012; 22:
1798–1812.
19. Rosenbloom KR, Armstrong J, Barber GP et al. The UCSC Genome Browser database:
2015 update. Nucleic Acids Res 2015; 43: D670–D681.
20. Mathelier A, Zhao X, Zhang AW et al. JASPAR 2014: an extensively expanded and updated
open-access database of transcription factor binding profiles. Nucleic Acids Res 2014; 42:
D142–D147.
21. Ben-Shmuel A, Shvab A, Gavert N et al. Global analysis of L1-transcriptomes identified
IGFBP-2 as a target of ezrin and NF-kappaB signaling that promotes colon cancer
progression. Oncogene 2013; 32: 3220–3230.
22. Lang CH, Nystrom GJ, Frost RA. Regulation of IGF binding protein-1 in hep G2 cells by
cytokines and reactive oxygen species. Am J Physiol 1999; 276: G719–G727.
23. Martinez FO, Gordon S, Locati M et al. Transcriptional profiling of the human monocyte-to-
macrophage differentiation and polarization: new molecules and patterns of gene
expression. J Immunol 2006; 177: 7303–7311.
24. Shin YH, Lee GW, Son KN et al. Promoter analysis of human CC chemokine CCL23 gene in
U937 monocytoid cells. Biochim Biophys Acta 2007; 1769: 204–208.
25. Singh AK, Battu A, Mohareer K et al. Transcription of human resistin gene involves an
interaction of Sp1 with peroxisome proliferator-activating receptor gamma (PPARgamma).
PLoS One 2010; 5: e9912.
26. Zeyda M, Gollinger K, Kriehuber E et al. Newly identified adipose tissue macrophage
populations in obesity with distinct chemokine and chemokine receptor expression. Int J
Obes (Lond) 2010; 34: 1684–1694.
27. Levin AD, Wildenberg ME, van den Brink GR. Mechanism of action of Anti-TNF therapy in
inflammatory bowel disease. J Crohns Colitis 2016; 10: 989–997.
28. van der Burg B, Liden J, Okret S et al. Nuclear factor-kappa B repression in antiinflam-
mation and immunosuppression by glucocorticoids. Trends Endocrinol Metab 1997; 8:
152–157.
29. Truss M, Beato M. Steroid hormone receptors: interaction with deoxyribonucleic acid and
transcription factors. Endocr Rev 1993; 14: 459–479.
30. Bergin DA, Reeves EP, Meleady P et al. alpha-1 Antitrypsin regulates human neutrophil
chemotaxis induced by soluble immune complexes and IL-8. J Clin Invest 2010; 120:
4236–4250.
31. Ozeri E, Mizrahi M, Shahaf G et al. alpha-1 antitrypsin promotes semimature, IL-10-
producing and readily migrating tolerogenic dendritic cells. J Immunol 2012; 189: 146–153.
32. Ray A, Gao X, Ray BK. Role of a distal enhancer containing a functional NF-kappa B-binding
site in lipopolysaccharide-induced expression of a novel alpha 1-antitrypsin gene. J Biol
Chem 1995; 270: 29201–29208.
33. Rioja I, Hughes FJ, Sharp CH et al. Potential novel biomarkers of disease activity in
rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor
necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
Arthritis Rheum 2008; 58: 2257–2267.
34. Singh UP, Singh NP, Murphy EA et al. Chemokine and cytokine levels in inflammatory bowel
disease patients. Cytokine 2016; 77: 44–49.
35. Kim J, Kim YS, Ko J. CK beta 8/CCL23 induces cell migration via the Gi/Go protein/PLC/PKC
delta/NF-kappa B and is involved in inflammatory responses. Life Sci 2010; 86: 300–308.
36. Kaser S, Kaser A, Sandhofer A et al. Resistin messenger-RNA expression is increased by
proinflammatory cytokines in vitro. Biochem Biophys Res Commun 2003; 309: 286–290.
37. Sasayama D, Hori H, Nakamura S et al. Increased protein and mRNA expression of resistin
after dexamethasone administration. Horm Metab Res 2015; 47: 433–438.
38. Tanaka N, Kusunoki N, Kusunoki Y et al. Resistin is associated with the inflammation process
in patients with systemic autoimmune diseases undergoing glucocorticoid therapy:
comparison with leptin and adiponectin. Mod Rheumatol 2013; 23: 8–18.
39. Eivindson M, Gronbaek H, Flyvbjerg A et al. The insulin-like growth factor (IGF)-system in
active ulcerative colitis and Crohn's disease: relations to disease activity and corticosteroid
treatment. Growth Horm IGF Res 2007; 17: 33–40.
40. Linker RA, Maurer M, Gaupp S et al. CNTF is a major protective factor in demyelinating CNS
disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat Med 2002; 8:
620–624.
41. Sendtner M, Schmalbruch H, Stockli KA et al. Ciliary neurotrophic factor prevents degeneration
of motor neurons in mouse mutant progressive motor neuronopathy. Nature 1992; 358:
502–504.
42. Tinkle CL, Lechler T, Pasolli HA et al. Conditional targeting of E-cadherin in skin: insights into
hyperproliferative and degenerative responses. Proc Natl Acad Sci USA 2004; 101:
552–557.
43. Wurbel MA, Le Bras S, Ibourk M et al. CCL25/CCR9 interactions are not essential for colitis
development but are required for innate immune cell protection from chronic experimental
murine colitis. Inflamm Bowel Dis 2014; 20: 1165–1176.
44. Huang SC, Everts B, Ivanova Y et al. Cell-intrinsic lysosomal lipolysis is essential for
alternative activation of macrophages. Nat Immunol 2014; 15: 846–855.
45. Taganov KD, Boldin MP, Chang KJ et al. NF-kappaB-dependent induction of microRNA
miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl
Acad Sci USA 2006; 103: 12481–12486.
46. Eisenberg I, Alexander MS, Kunkel LM. miRNAS in normal and diseased skeletal muscle. J
Cell Mol Med 2009; 13: 2–11.
47. Olivieri F, Lazzarini R, Recchioni R et al. MiR-146a as marker of senescence-associated
pro-inflammatory status in cells involved in vascular remodelling. Age (Dordr) 2013; 35:
1157–1172.
48. Ghorpade DS, Sinha AY, Holla S et al. NOD2-nitric oxide-responsive microRNA-146a
activates Sonic hedgehog signaling to orchestrate inflammatory responses in murine model
of inflammatory bowel disease. J Biol Chem 2013; 288: 33037–33048.
49. Zhao JL, Rao DS, Boldin MP et al. NF-kappaB dysregulation in microRNA-146a-deficient
mice drives the development of myeloid malignancies. Proc Natl Acad Sci USA 2011; 108:
9184–9189.
50. Heier CR, Damsker JM, Yu Q et al. VBP15, a novel anti-inflammatory and membrane-
stabilizer, improves muscular dystrophy without side effects. EMBO Mol Med 2013; 5:
1569–1585.
51. Fasseu M, Treton X, Guichard C et al. Identification of restricted subsets of mature microRNA
abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel
disease. PLoS One 2010; 5: pii: e13160.
52. Damsker JM, Conklin LS, Sadri S et al. VBP15, a novel dissociative steroid compound,
reduces NFκB-induced expression of inflammatory cytokines in vitro and symptoms of
murine trinitrobenzene sulfonic acid-induced colitis. Inflamm Res 2016; 65: 737–743.
53. Levine A, Griffiths A, Markowitz J et al. Pediatric modification of the Montreal classification for
inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011; 17:
1314–1321.
Clinical and Translational Gastroenterology is an open-
access journal published by Nature Publishing Group.
This work is licensed under a Creative Commons Attribution-
NonCommercial-ShareAlike 4.0 International License. The images or
other third party material in this article are included in the article’s
Creative Commons license, unless indicated otherwise in the credit line;
if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to
reproduce the material. To view a copy of this license, visit http://
creativecommons.org/licenses/by-nc-sa/4.0/
Supplementary Information accompanies this paper on the Clinical and Translational Gastroenterology website (http://www.nature.com/ctg)
Anti-Inflammatory Biomarker Discovery
Heier et al.
8
Clinical and Translational Gastroenterology
